论文部分内容阅读
目的观察孟鲁司特联合舒利迭治疗中重度慢阻肺(COPD)非急性发作期的疗效。方法选取中重度COPD非急性发作期患者104例,随机分为治疗组和对照组各52例,两组均予常规对症支持治疗。对照组给予舒利迭吸入,治疗组在对照组的基础上加服孟鲁司特。12周为1个疗程。2个疗程后评价疗效。结果治疗组患者6MWT与对照组患者6MWT测定结果比较差异有统计学意义(P<0.05);治疗组治疗后肺功能各指标改善水平均明显高于对照组,差异均有统计学意义(P<0.05)。结论采用孟鲁司特联合舒利迭治疗中重度COPD非急性发作期疗效显著,可显著改善患者肺功能,提高生活质量。
Objective To observe the efficacy of montelukast and seretide in the treatment of non-acute exacerbation of moderate and severe chronic obstructive pulmonary disease (COPD). Methods A total of 104 patients with moderate-to-severe COPD without acute exacerbation were randomly divided into treatment group (n = 52) and control group (n = 52). Both groups were given conventional symptomatic supportive care. The control group was given seretide inhalation, and the treatment group was given montelukast on the basis of the control group. 12 weeks for a course of treatment. After 2 courses evaluate the curative effect. Results The difference of 6MWT between the 6MWT group and the control group was statistically significant (P <0.05). The improvement of each index of the pulmonary function after treatment in the treatment group was significantly higher than that of the control group (P < 0.05). Conclusion Montelukast combined with seretide in the treatment of moderate-to-severe non-acute exacerbation of COPD significant effect, can significantly improve lung function and improve quality of life.